$ARDX Partner Kyowa Hakko Announces Initiation of a Ph2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan. Triggers $5M milestone payment to Ardelyx httpswww.prnewswire.comnewsreleasesardelyxcollaborationpartnerkyow

$ARDX Partner, Kyowa Hakko Announces Initiation of a Ph2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan. Triggers $5M milestone payment to Ardelyx https://www.prnewswire.com/news-releases/ardelyx-collaboration-partner-kyow

$ARDX Partner, Kyowa Hakko Announces Initiation of a Ph2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan. Triggers $5M milestone payment to Ardelyx https://www.prnewswire.com/news-releases/ardelyx-collaboration-partner-kyowa-hakko-kirin-announces-initiation-of-a-phase-2-clinical-study-of-tenapanor-for-hyperphosphatemia-patients-on-dialysis-in-japan-300791480.html …

More From BioPortfolio on "$ARDX Partner, Kyowa Hakko Announces Initiation of a Ph2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan. Triggers $5M milestone payment to Ardelyx https://www.prnewswire.com/news-releases/ardelyx-collaboration-partner-kyow"